Page 509 - Read Online

Wu et al. J Cancer Metastasis Treat 2020;6:40 I http://dx.doi.org/10.20517/2394-4722.2020.77 Page 9 of 9

bullous pemphigoid. J Immunother Cancer 2016;4:20.
29. Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2016;2:442-4.
30. Mochel MC, Ming ME, Imadojemu S, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for
metastatic melanoma. J Cutan Pathol 2016;43:787-91.
31. Lomax AJ, Ge L, Anand S, McNeil C, Lowe P. Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving
pembrolizumab and previously treated with ipilimumab. Australas J Dermatol 2016:57:333-5.
32. Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P. Bullous pemphigoid, an autoantibody-mediated disease, is a
novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 2016;26:413-6.
33. Hirotsu K, Chiou AS, Chiang A, Kim J, Kwong BY, Pugliese S. Localized bullous pemphigoid in a melanoma patient with dual exposure
to PD-1 checkpoint inhibition and radiation therapy. JAAD Case Rep 2017;3:404-6.
34. Parakh S, Nguyen R, Opie JM, Andrews MC. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with
pembrolizumab for metastatic melanoma. Australas J Dermatol 2017:58:e109-12.
35. Kwon CW, Land AS, Smoller BR, Scott G, Beck LA, Mercurio MG. Bullous pemphigoid associated with nivolumab, a programmed cell
death 1 protein inhibitor. J Eur Acad Dermatol Venereol 2017;31:e349-50.
36. Bandino JP, Perry DM, Clarke CE, Marchell RM, Elston DM. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-
like disease and eruptive keratoacanthomas featuring combined histopathology. J Eur Acad Dermatol Venereol 2017:31:e378-80.
37. Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R. Severe bullous pemphigoid associated with pembrolizumab therapy for
metastatic melanoma with complete regression. Clin Exp Dermatol 2017;42:309-12.
38. Wada N, Uchi H, Furue M. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen
XVII. J Dermatol 2017;44:e240-1.
39. Zumelzu C, Alexandre M, Le Roux C, et al. Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1/
programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab
therapy for metastatic melanoma and review of the literature. Front Med (Lausanne) 2018;5:268.
40. Hanley T, Papa S, Saha M. Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma. JRSM Open
2018;9:2054270418793029.
41. Panariello L, Fattore D, Annunziata MC, Piantedosi F, Gilli M, Fabbrocini G. Bullous pemphigoid and nivolumab: dermatologic
management to support and continue oncologic therapy. Eur J Cancer 2018;103:284-6.
42. Kuwatsuka Y, Iwanaga A, Kuwatsuka S, et al. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant
melanoma after unsuccessful treatment with nivolumab. J Dermatol 2018;45:e21-2.
43. Haug V, Behle V, Benoit S, et al. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma. Br J
Dermatol 2018;179:993-4.
44. Sturque J, Boralevi F, Fricain JC. Nivolumab-induced oral and cutaneous bullous pemphigoid: a case report. J Oral Med Oral Surg
2019;25:17.
45. Sibaud V, Vigarios E, Siegfried A, Bost C, Meyer N, Pages-Laurent C. Nivolumab-related mucous membrane pemphigoid. Eur J Cancer
2019;121:172-6.
46. Bezinelli LM, Eduardo FP, Migliorati CA, et al. A severe, refractory case of mucous membrane pemphigoid after treatment with
pembrolizumab: brief communication. J Immunother 2019;42:359-62.
47. Leavitt E, Holland V. A case of atezolizumab-induced photodistributed bullous pemphigoid. Dermatol Ther 2019;32:e12924.
48. Anedda J, Atzori L, Rongioletti F, Pilloni L. Nivolumab bullous pemphigoid: case description and literature review. J Clin Exp Pathol
2019;9:364.
49. Fontecilla NM, Khanna T, Bayan CAY, Antonov NA, Geskin LJ. Bullous pemphigoid associated with a new combination checkpoint
inhibitor immunotherapy. J Drugs Dermatol 2019;18:103-4.
50. Virgen CA, Nguyen TA, Di Raimondo C, et al. Bullous pemphigoid associated with cemiplimab therapy in a patient with locally
advanced cutaneous squamous cell carcinoma. JAAD Case Rep 2020;6:195-7.